Next Article in Journal
Prognostic Protein Biomarker Screening for Thyroid Carcinoma Based on Cancer Proteomics Profiles
Next Article in Special Issue
Mortality Risk and Urinary Proteome Changes in Acute COVID-19 Survivors in the Multinational CRIT-COV-U Study
Previous Article in Journal
Comparative Short- and Long-Term Effectiveness and Safety of Pramipexole and Aripiprazole Augmentation in Treatment-Resistant Unipolar Depression: An Observational Study
Previous Article in Special Issue
Uncovering the Contrasts and Connections in PASC: Viral Load and Cytokine Signatures in Acute COVID-19 versus Post-Acute Sequelae of SARS-CoV-2 (PASC)
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 12
Issue 9
10.3390/biomedicines12092065
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

New Onset of Acute and Chronic Hepatic Diseases Post-COVID-19 Infection: A Systematic Review

by
Ahamed Lebbe
1,†,
Ali Aboulwafa
1,†,
Nuran Bayraktar
1,
Beshr Mushannen
1,
Sama Ayoub
1,
Shaunak Sarker
1,
Marwan Nour Abdalla
1,
Ibrahim Mohammed
2,
Malik Mushannen
3,
Lina Yagan
4 and
Dalia Zakaria
5,*
1
Medical Department, Weill Cornell Medicine-Qatar, Doha 24144, Qatar
2
Department of Medicine, Albany Medical College, New York, NY 12208, USA
3
Department of Medicine, New York-Presbyterian Brooklyn Methodist Hospital, New York, NY 12208, USA
4
Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
5
Premedical Department, Weill Cornell Medicine-Qatar, Doha 24144, Qatar
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Biomedicines 2024, 12(9), 2065; https://doi.org/10.3390/biomedicines12092065
Submission received: 11 July 2024 / Revised: 11 August 2024 / Accepted: 13 August 2024 / Published: 10 September 2024
(This article belongs to the Special Issue Latest Research in Post-COVID (Long COVID): Pathological and Treatment Studies of Sequelae and Complications—2nd Edition)
Browse Figures
Versions Notes

Abstract

:
The SARS-CoV-2 virus caused a pandemic in the 2020s, which affected almost every aspect of life. As the world is recovering from the effect of the coronavirus, the concept of post-COVID-19 syndrome has emerged. Multiple organ systems have been implicated, including the liver. We aim to identify and analyze the reported cases of severe and long-term parenchymal liver injury post-COVID-19 infection. Several databases were used to conduct a comprehensive literature search to target studies reporting cases of severe and long-term parenchymal liver injury post-COVID-19 infection. Screening, data extraction, and cross checking were performed by two independent reviewers. Only 22 studies met our inclusion criteria. Our results revealed that liver steatosis, non-alcoholic fatty liver disease (NAFLD), and cirrhosis were the most reported liver associated complications post-COVID-19 infection. Moreover, complications like acute liver failure, hepatitis, and liver hemorrhage were also reported. The mechanism of liver injury post-COVID-19 infection is not fully understood. The leading proposed mechanisms include the involvement of the angiotensin-converting enzyme-2 (ACE-2) receptor expressed in the liver and the overall inflammatory state caused by COVID-19 infection. Future studies should incorporate longer follow-up periods, spanning several years, for better insight into the progression and management of such diseases.

1. Introduction

A new coronavirus emerged in 2019, causing a debilitating pandemic in 2020. The coronavirus was called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the disease caused was called coronavirus disease 2019 (COVID-19). The infection ranged from asymptomatic and mild to severe, with infection of lung parenchyma and multiorgan dysfunction, often affecting those with comorbidities and underlying immunodeficiency [1].
As the world recovered from the pandemic, the concept of “long COVID” or post-acute sequelae of SARS-CoV-2 infection (PASC) and “post-COVID syndrome” came about as patients who recovered from the illness experienced a wide variety of symptoms. Some of the complications were short term. Symptoms occurring between 4 and 12 weeks after infection are referred to as post-COVID-19 condition, as per the Centers for Disease Control and Prevention (CDC), whereas long COVID typically refers to issues persisting after the 12-week period [2].
The SARS-CoV-2 virus affects many organs throughout the body, and the liver and biliary system have been implicated in long COVID manifestations [3]. SARS-CoV-2 is among many viruses that are associated with liver disease. Hepatitis associated with viral hemorrhagic fevers brought on by the likes of Dengue fever, as well as fulminant liver necrosis induced by the likes of adenoviruses, are just some examples of this [4]. Herpes viruses, in their unique manner, can remain dormant and reactivate at later stages of life, causing catastrophic disease ranging from fulminant hepatitis to lymphocyte proliferation and transformation into lymphoma [4]. Similar to SARS-CoV-2, respiratory viruses such as influenza viruses often display milder symptoms that more closely represent that of SARS-CoV-2. Many patients have abnormal liver chemistries post-COVID-19 infection; however, the clinical implications and long-term manifestations of liver injury inflicted by COVID-19 are not well defined in the literature. The liver injury observed is usually classified by deriving an R-factor suggestive of a hepatocellular or cholestatic pattern of injury. Parenchymal liver injury comprises a variety of lesions that include inflammatory infiltration, hepatocellular degenerative changes, and liver cell death via necrosis or apoptosis. Inflammatory infiltration is a common characteristic in cases of hepatitis and can sometimes go unnoticed through lab studies; hence, it is confirmed via imaging. Steatosis, bile stasis, ballooning, and Mallory–Denk bodies are just some features of hepatocellular degenerative changes observed in fatty liver diseases, such as NAFLD. A clear distinction between steatosis and steatohepatitis is important to observe in these cases, given the latter’s greater potential to progress to fibrosis and cirrhosis. These two characteristics can often be seen in conjunction, along with sclerosis as a long-term outcome. These characteristics often have a temporal relationship in parenchymal liver injury. Inflammation transitions to hepatocellular changes in response to the acute injury that may then progress gradually into cell death and its associated changes (fibrosis, sclerosis, etc.). Hepatocellular injury is specific to liver parenchyma, while cholestatic injury is reflective of injury that is biliary in origin. The degree of liver injury correlates to the severity of COVID-19 infection. Conversely, patients with pre-existing liver disease were noted to have an increased risk for severe COVID-19 infection and intensive care unit (ICU) admission [5]. Interestingly, non-alcoholic fatty liver disease (NAFLD) has been associated with a longer viral shedding time [5].
The objective of this systematic review is to look at the patterns and manifestations of parenchymal liver injury reported in individuals either after recovering from COVID-19 infection or those that occurred during the active infection and lasted and/or required treatment for 12 weeks or longer.

2. Materials and Methods

The preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement was used to develop the protocol of this systematic review [6].

2.1. Information Sources and Search Strategy

This study is part of a large project that investigates the long-term and severe complications of COVID-19. A comprehensive search was conducted by an information professional who prioritized sensitivity to retrieve all relevant studies. The following databases were searched in October 2023: PubMed, Medline (Ovid, 1946–Current), Embase (Ovid, 1974–2021), Scopus, Web of Science, Science Direct, and Cochrane Library. The search was designed around keywords and controlled vocabulary that focused on “Long COVID” and variants (see Supplementary Materials S1 for full search details). No language or date restrictions were used. All database search results were imported into EndNote (version 19) and exported to Covidence, where duplicates were removed prior to initial screening (Supplementary Materials S1).

2.2. Eligibility Criteria

No restrictions were made based on gender, age, or country. Duplicates were removed and any articles that were not in English or did not have primary data, such as review articles, were excluded from the study. All conference abstracts were excluded, and only full articles were included. During the full-text screening, any studies that reported parenchymal liver injury were included if a clear diagnosis was reported. Any studies reporting only liver function test (LFT) derangement were excluded. We only included severe and/or long-term parenchymal liver complications. The inclusion criteria related to this point included any patients who developed a parenchymal liver injury after recovering from COVID-19. If the injury was diagnosed after at least a month post-COVID-19 diagnosis or if the study reported that anti-SARS-CoV-2 IgG but not IgM antibodies were detected, the study was included. The studies that reported parenchymal liver injury diagnosis during the active COVID-19 infection were included only if the patient did not recover from the liver injury within 12 weeks or required treatment for 12 weeks or more. The study was also included if the patient died within 12 weeks, which indicates severity. Any cases with parenchymal liver injury that were diagnosed during the active infection of COVID-19 and fully recovered within less than 12 weeks were excluded.

2.3. Study Selection and Data Collection

Title, abstract screening, and full-text screening were conducted by two independent reviewers for each study using Covidence. Disagreements were resolved by consensus. Data were extracted and cross checked by two independent reviewers.

2.4. Data Items

Demographic and clinical data, including age, sex, comorbidities, treatments, and outcomes, were collected. Continuous variables were expressed as mean ± standard deviation or range of results. Categorical variables were expressed as percentages.

2.5. Risk of Bias and Quality Assessment

The quality assessment was conducted using different methods depending on the type of study. The Newcastle–Ottawa Quality Assessment Scale (NOS) was used to assess the cohort studies [7]. The scale developed by Murad et al. was used to assess the case reports and case series [8]. Quality assessment was conducted and cross checked by two independent reviewers.

2.6. Data Analysis

The parenchymal liver disorders reported by the included studies were classified under the following categories: steatosis and NAFLD; liver fibrosis, sclerosis, and cirrhosis; hepatitis; acute liver failure; liver inflammation by imaging; hepatomegaly; and any other parenchymal liver disorders that do not fall under the above categories.

3. Results

Figure 1 shows the flow diagram of our protocol. After removing the duplicates, the titles and abstracts of 38148 studies were screened, of which 273 were selected for full-text screening. Only 22 studies met our inclusion criteria. Of the two hundred fifty-one excluded studies, one hundred thirty-four were irrelevant, eighteen had no primary data, forty-one were conference abstracts, forty-three did not have enough data, fourteen were not in English, and one was duplicate. Supplementary Table S1 summarizes the demographic and clinical data of the included subjects as well as the quality assessment score for each study [9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30].

3.1. Types of Studies and Demographic Data

Of the twenty-two included studies, nine were case reports, ten were cohort studies, one was a case series and one was a cross-sectional study. Among the twenty-two included studies, two were from the USA, three from India, four from the UK, two from Indonesia, two from Latvia, two from Romania, and one from Brazil, Israel, Taiwan, UAE, China, Hungary, and Italy each.
The total number of patients reported by 22 studies (case series and case reports) was 161,594. Of these patients, 500 sustained post-COVID-19 parenchymal liver disease. Approximately 48% of patients were males. Furthermore, the age of the included patients ranged from 3 months to 88 years (Supplementary Table S1).

3.2. Clinical Data

The reported disorders related to the liver parenchyma post-COVID-19 were categorized into: steatosis and NAFLD, liver fibrosis, sclerosis, cirrhosis, acute liver failure, liver inflammation by imaging, hepatomegaly, hepatitis, and other post-COVID-19 parenchymal liver diseases that do not fall under the previous groups. An overlap exists, as certain studies reported various mechanisms of parenchymal liver injury. Therefore, some studies were included under multiple categories and some patients were counted under different categories (Supplementary Table S1). Figure 2 summarizes the types of reported parenchymal injury post-COVID-19 infection and the reported outcomes.

3.2.1. Steatosis and NAFLD

Steatosis and NAFLD were reported by 7 studies on 140 patients whose age ranged from 52 to 74 years. This was excluding Ma et al., who reported that the hazard ratio (HR) of developing NAFLD was 1.33 (1.15 to 1.55 with p < 0.001) in patients who recovered from COVID-19 as compared to healthy controls.
Of the included 140 patients, 35 were reported to have steatosis, and 105 had NAFLD. The prevalence of steatosis among COVID-19 patients was 26% according to Roman et al. at the 6 month follow-up. Out of the 140 patients, 24 had severe COVID-19, but no deaths were reported (Table 1). Figure 3a summarizes the reported types of post-COVID-19 steatosis/NAFLD.

3.2.2. Liver Fibrosis, Sclerosis, and Cirrhosis

Post-COVID-19 liver fibrosis, sclerosis, and cirrhosis were reported by four studies on 22 patients (Table 2).

3.2.3. Hepatitis

Post-COVID-19 hepatitis was reported by four studies on six patients whose age ranged from 8 months to 25 years. Of the six patients, none of them were reported to have severe COVID-19, all six of them recovered from liver injury, and no deaths were reported (Table 3). Figure 3b summarizes the reported types of post-COVID-19 hepatitis.

3.2.4. Acute Liver Failure

Acute liver failure was reported by three studies on three patients whose age ranged from 3 months to 65 years. Of the three patients, none of them were reported to have severe COVID-19, and two of them had remarkable complications of NAFLD and Hemophagocytic lymphohistiocytosis following the liver insult, but no deaths were reported (Table 4).

3.2.5. Liver Inflammation by Imaging

Liver inflammation was reported by two studies on 29 patients whose age ranged from 56 to 88 years. Of the twenty-nine patients, seven of them were reported to have severe COVID-19 but no deaths were reported (Table 5).

3.2.6. Hepatomegaly

Hepatomegaly was reported by two studies on 41 patients. Of the 41, 20 were reported to have hepatomegaly and 21 had increased liver volume by imaging. No deaths were reported (Table 6). Figure 3c summarizes the reported types of post-COVID-19 hepatomegaly.

3.2.7. Other Parenchymal Liver Diseases

There were 11 further studies describing various other liver diseases experienced after COVID-19 in 225 patients (Table 7). Ayoubkhani et al. described 140 patients having unspecified chronic liver disease and reported that chronic liver disease was diagnosed in 0.3% of patients after discharge due to COVID-19 infection [9]. Daid et al. reported a case of intraparenchymal liver hemorrhage in a 43-year-old, and Liemarto et al. reported a case of liver hemorrhage with abscess and necrosis in a 49-year-old patient, who passed away on the 20th day of admission (Table 6 and Figure 3d) [18,24].

4. Discussion

Numerous studies have explored the hepatic manifestations associated with COVID-19 infection. This systematic review compiles data reporting parenchymal liver injury following COVID-19 infection to elucidate the underlying mechanisms, prevalence, and clinical implications of hepatic involvement as one of the severe and long-term complications of COVID-19.
This systematic review involves 22 studies from 13 different countries reporting 500 patients who had post-COVID-19 parenchymal liver injury. The most common manifestation was steatosis and NAFLD in addition to acute liver failure, hepatitis, fibrosis, and sclerosis.

4.1. Post-COVID-19 Steatosis and NAFLD

Non-alcoholic fatty liver disease (NAFLD), now referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), encompasses a spectrum of liver conditions characterized by excessive fat accumulation in the liver without significant alcohol consumption or other secondary causes. NAFL is defined by hepatic steatosis without evidence of hepatocellular injury, such as ballooning degeneration of hepatocytes, while Nonalcoholic steatohepatitis (NASH) involves hepatic steatosis accompanied by inflammation and hepatocellular injury, which can progress to fibrosis, cirrhosis, and liver-related morbidity and mortality (Han S. et al.) [31]. The term MASLD was suggested to more accurately reflect the pathogenesis of the disease, with the diagnosis being made in the presence of hepatic steatosis and one of the following criteria: overweight/obesity, type 2 diabetes mellitus, and evidence of metabolic dysregulation [30]. The development of NAFLD is also influenced by genetic factors, with many studies having identified genetic drivers of NAFLD, beyond the established factors of metabolic syndrome and insulin resistance. Notably, the phospholipase domain-containing protein 3 (PNPLA3) and transmembrane 6 superfamily member 2 (TM6SF2) nucleotide polymorphisms were found to affect the development and progression of the disease [30]. Genes involved in carbohydrate and lipid metabolism, insulin signaling pathways, inflammatory pathways, oxidative stress, and fibrogenesis have also been linked with NAFLD/NASH development and progression [30]. Mitochondrial dysfunction is the key mediator triggering oxidative stress and is brought on by an imbalance of oxidants and antioxidants. Most notably, the uncoupling between β-oxidation, the tricarboxylic acid (TCA) cycle, and the electron transport chain (ETC) frequently results in inefficient lipid metabolism and reactive oxygen species (ROS) overproduction in the liver [32]. The capacity of antioxidant defense is further suppressed by ROS overproduction, leading to further oxidative damage [32].
Steatosis and NAFLD were among the most reported post-COVID-19 liver manifestations as reported by seven studies on 140 patients, of which 24 had severe COVID-19. Pesti et al. found that 15 of the 147 autopsies had steatosis [23]. However, a correlation between the severity of infection and the development of steatosis was not established by Pestii et al. [23]. However, Dennies et al. reported a more frequent incidence of steatosis in symptomatic groups [11]. Roman et al. reported that 26% of the patients had steatosis at the 6 month follow-up [25]. Furthermore, they reported that patients with severe COVID-19 were more likely to have persistent alanine transaminase (ALT) elevation at 6 months compared to those with non-severe COVID-19. Bende et al. investigated the outcomes of COVID-19 patients with and without pulmonary injury, delineating that pulmonary injury correlates with a severe disease course [27]. They found that patients with pulmonary injury were more likely to have steatosis. Ma et al. reported that the hazard ratio (HR) of developing post-COVID-19 NAFLD was 1.33 (CI 95%, 1.15 to 1.55 with p < 0.001) as compared to healthy controls [19]. Radzina et al. used attenuation imaging (ATI) to detect steatosis and found that post-COVID-19 individuals had significantly increased steatosis compared to healthy controls [22]. Milic et al. reported that 55% of patients had NAFLD on follow-up, while only 37% were calculated to have NAFLD during the initial admission [26]. This finding correlated to the weight changes during and after COVID-19 (–6 kg during, +5 kg after), leading the authors to suggest that the loss of muscle during the acute phase and a buildup of fat in the liver during the chronic/post-acute phase is what leads to NAFLD in individuals who recovered from COVID-19 infection.
A prominent theory regarding the mechanism of liver injury is that the angiotensin-converting enzyme-2 (ACE-2) receptor serves as a gateway for the virus. The spike protein on the virus surface binds to the ACE-2 receptor, facilitating this process. The ACE-2 receptor is reported to be expressed in hepatocytes and more frequently in cholangiocytes. Although there is not much evidence that the biliary tree is affected more than hepatocytes, interestingly, it is highly expressed in the endothelial layer of small blood vessels but is absent in the sinusoidal epithelium [33]. SARS-CoV-2 competes with Ang II for binding to ACE2, and when the virus binds, it inhibits ACE2 activity and decreases its expression on the cell membrane [34]. This can potentially disrupt the balance of the renin–angiotensin–aldosterone system (RAAS), leading to angiotensin-2 mediated vasoconstriction and a decrease in angiotensin (1-7)-mediated vasodilation that may contribute to inflammation [35]. Additionally, the kallikrein–kinin system (KKS), often considered an antagonist to the RAAS, mitigates inflammatory effects by reducing the generation of reactive oxygen species and lowering blood pressure [36]. The internalization of ACE-2 due to viral binding can further disrupt this balance by increasing bradykinin levels, which can activate the bradykinin (B) 2 receptor and enhance inflammation, particularly through the cytokine storm [37].

4.2. Post-COVID-19 Liver Fibrosis, Sclerosis, and Cirrhosis

Liver fibrosis occurs due to the excessive accumulation of extracellular matrix proteins, including collagen, in the liver, as a result of chronic liver injury or persistent inflammation [38]. Cirrhosis is the most advanced stage of liver fibrosis, where extensive scarring has disrupted the normal architecture of the liver, leading to the formation of nodules and impaired liver function. It is characterized by the presence of regenerative nodules surrounded by fibrous bands [39]. Our results revealed that three studies reported fibrosis and two studies reported cirrhosis as post-COVID-19 complications. Kolesova et al. reported that 65% of patients with acute COVID-19 exhibited an abnormal Fibrosis-4 Index (FIB-4), possibly serving as a derivative for systemic inflammation, hepatocellular damage, and infection severity [17]. FIB-4 scores may have been falsely elevated in the acute setting in the setting of inflammation, and a decrease in the index was observed post-recovery. In the post-COVID-19 group, 5% had increased levels of FIB-4. A history of liver disease did not influence FIB-4 in the post-COVID-19 group, suggesting that COVID-19 infection is the cause of liver fibrosis. Therefore, it is essential to monitor liver chemistries post-COVID-19 to facilitate early diagnosis and prevent liver damage [17]. Similarly, Pesti et al. reported fibrosis post-COVID-19 in seven patients out of one hundred fifty in an autopsy study [23]. Moreover, significantly increased fibrosis, viscosity, and steatosis were reported by Radzina et al. in post-COVID-19 patients compared to controls [22]. Finally, they reported a significantly positive relationship between ALT, gamma-glutamyl transferase (GGT), and body mass index (BMI) with liver fibrosis seen on shear wave dispersion (SWD).
Conversely, Pesti et al. suggested that fibrosis is likely due to pre-existing comorbidities or treatments rather than COVID-19 infections, as they found no association with the severity of COVID-19 and fibrosis or cirrhosis [23]. They observed signs of apoptosis in histopathology slides of the liver without detectable COVID-19 protein/RNA. This suggests that liver damage may occur indirectly due to other factors such as hypoxia caused by COVID-19 rather than through direct cytopathic mechanisms.

4.3. Post-COVID-19 Hepatitis

Hepatitis is inflammation of the liver, which can be caused by various factors such as viruses, heavy alcohol use, certain medications, and autoimmune disorders. This inflammation can lead to swelling and damage to the liver, affecting its function [40]. A total of six patients were reported to have hepatitis across four studies. Most patients were asymptomatic. Daga et al. described a patient with abdominal pain and nausea, who was later diagnosed with acute cholecystitis in addition to hepatitis [30]. Shorbagi et al. also reported a patient with abdominal pain and diarrhea who was found to have ulcerative colitis, potentially confounding the clinical picture [28]. However, it was later found that the patient had ulcerative colitis-like syndrome, which may have caused the symptoms. The patient was diagnosed with autoimmune hepatitis, identified by an elevated antinuclear antibody (ANA) and anti-smooth muscle antibody titers. Three patients were reported with cholestasis along with hepatitis by Cooper et al. and Dragenescu reported a case of isolated hepatitis in a 21-year-old [13,14]. All patients had mild COVID-19, which was supportively managed.

4.4. Post-COVID-19 Acute Liver Failure

Acute liver failure is characterized by the rapid deterioration of liver function, leading to the development of hepatic encephalopathy and impaired synthetic function. This often results in coagulopathy and altered mental status in individuals without preexisting liver disease [41]. Acute liver failure was reported by three studies on three patients, excluding Ma et al., who did not report data on liver failure [19]. Cooper et al. reported that two patients, one 3 months old and one 5 months old, required liver transplant [14]. The first case had a mild infection, but both cases presented with encephalopathy and deteriorated over the hospital course, requiring liver transplantation at the end. The case reported by Anguiano-Albarran et al. also presented with encephalopathy and renal failure [20]. The patient was treated with supportive measures for liver failure with fluid resuscitation and intravenous albumin. The patient recovered and was ultimately followed-up as a case of NAFLD.
It was proposed that the cytokine storm seen in critically ill COVID-19 patients is marked by an overactive immune response leading to biliary sclerotic alterations and liver dysfunction, which in turn contributes to multiorgan failure [20].

4.5. Post-COVID-19 Liver Inflammation by Imaging

Liver inflammation is a condition characterized by the swelling and damage of liver tissue. This inflammation is the body’s natural response to injury or infection [42]. Two studies reported 29 patients with liver inflammation on imaging via positron emission tomography (PET) scan: Bai et al., with magnetic resonance imaging (MRI), and Dennis et al. [10,11]. The imaging, conducted 16 days on average after discharge, showed that post-COVID-19 patients had significantly higher standardized uptake values (SUV)max and (SUV)avg compared to controls (p < 0.05) (Bai et al.). All patients had severe COVID-19, in addition to evidence of inflammation in various other organs. No follow-up data were reported by this study. On the other hand, Dennis et al. followed the patients over 4 months and showed that liver inflammation was detected to a greater extent in post-COVID-19 patients than controls. Furthermore, they reported that liver inflammation and fibrosis (referred to as fibro inflammation together) were associated with cognitive dysfunction.

4.6. Post-COVID-19 Hepatomegaly

Hepatomegaly is a physical finding that may suggest intrinsic liver dysfunction and is a non-specific finding in many liver-related conditions [43]. Hepatomegaly was reported by two studies on 41 patients. Dennis et al. reported increased liver volume in 10.4% of the patients who were followed after COVID-19 infection, which was significantly higher than the control group (p < 0.0001) [11]. Furthermore, Dennis et al. reported hepatomegaly in 20 of the patients in the follow-up cohort, and it was associated with a poor quality of life [12]. However, no specifics were mentioned regarding other symptoms or impairments. The study also mentioned that liver impairment was more common in obese individuals and women.

4.7. Other Post-COVID-19 Parenchymal Liver Disorders

Congestive hepatopathy is a liver disorder that occurs due to prolonged passive venous congestion of the liver, commonly because of right-sided heart failure [44]. Congestive hepatopathy was reported in one patient by Ahmed et al.; the patient was described to have dilated cardiomyopathy 2 weeks after his COVID-19 infection diagnosis with deranged liver chemistries, which resolved after diuresis [15]. This was attributed to either COVID-19 or drug-induced liver injury (DILI) from herbal medicine, which the patient took prior to admission. Deranged LFTs are very common following viral infections and are non-specific. Lai et al. reported a case of deranged LFTs with a calcified liver nodule seen on imaging, while Sai et al. reported a case of deranged LFTs and ascites [16,29]. However, the clinical significance and outcome were not clearly defined.
Two cases reported liver hemorrhage post-COVID-19 infection. Daid et al. described a patient who developed right upper quadrant (RUQ) pain and abnormal liver chemistries around 2 weeks after her admission for COVID-19 infection, which was treated with N-acetylcysteine [18]. The mechanism of injury was believed to involve endothelial cell damage caused by widespread vascular thrombosis accompanied by microangiopathy, as demonstrated in earlier studies [45,46]. The study suggests that physicians should consider intraparenchymal hepatic hemorrhage when encountering a patient who recovered from COVID-19 and is presenting with RUQ pain and elevated transaminase levels.
Hepatomegaly was reported by Liemarto et al. in a 49-year-old patient who presented, a month after his COVID-19 infection recovery, with abdominal pain and hepatomegaly [24]. It was found that the patient had two abscesses with hemorrhage, which were drained via an exploratory laparotomy (ex-lap). The study suggests many etiologies for liver damage after COVID-19 infection, including direct damage from SARS-CoV-2 proliferation in the liver, systemic changes due to inflammation, hypoxia, and microvascular damage [47]. It was also suggested to be drug-induced, as the patient received tocilizumab, which has been reported to cause liver injury through the IL-6 signaling relating to liver recovery [48].
Soldera et al. described a case of Hemophagocytic Lymphohistiocytosis (HLH) after COVID-19 infection [21]. HLH is a rare but severe systemic inflammatory syndrome characterized by excessive immune activation and an uncontrolled proliferation of activated lymphocytes and macrophages. This condition leads to widespread inflammation and tissue damage, affecting multiple organs [49]. The patient presented with high-grade fever, upper abdominal pain, and transaminitis. Bone marrow biopsy confirmed HLH, and it was successfully treated with etoposide, dexamethasone, and cyclosporine. Soldera et al. emphasized that severe cases of COVID-19 can result in liver injury, potentially leading to the development of HLH [21]. It is recommended to assess patients with post-COVID-19 liver injury for HLH, particularly if they exhibit a high-grade fever and have a history of rheumatic diseases. Prompt diagnosis and treatment of HLH following a COVID-19 infection are essential to avoid adverse outcomes [21].
A case of cold autoimmune hemolytic anemia was reported by Daga et al. a month after the resolution of the patient’s COVID-19 infection [30]. Of note, the patient also had acute icteric hepatitis. The hypothesized mechanism involves post-infectious impact of COVID-19 causing a viral reactivation, as the patient later tested positive for Epstein–Barr virus (EBV) IgG and cytomegalovirus (CMV) IgG titers. The presence of these antibodies, along with the autoimmune hemolytic anemia and the absence of other hepatic insults, suggests a possible relationship between the post-COVID inflammatory phase and latent viral pathogens.
An association between pulmonary injury and liver stiffness was reported by Bende et al. [27]; it was revealed that patients who had pulmonary injury had significantly higher liver stiffness measured via liver elastography after 3 to 11 weeks following the subsidization of symptoms from COVID-19 infection. Therefore, it was concluded that it may be beneficial to routinely investigate patients within 12 weeks following COVID-19 infection to detect early signs of fibrosis and prevent progression.
Interestingly, Ayoubkhani et al. looked at rates of chronic liver disease after COVID-19 infection and found that chronic liver disease was diagnosed in 0.3% of patients after discharge, and this was 2.8 times more frequently diagnosed than controls [9]. However, the types of liver disease were not reported.

4.8. Study Limitations

The limitations of this study included the possible overlap between the categories of the parenchymal liver disorders and between the hepatobiliary and parenchymal injury. Patients with multiple types of injury were reported by some studies. These patients were clustered without describing the individual cases. Therefore, some patients were counted multiple times under different categories due to the inability to specify which patient had which combination of disorders. The small number of the included studies is another limitation, which is attributed to excluding conference abstracts. Only full article journal publications were selected to maintain the quality of the included studies and to avoid duplication when the work is published in both conferences and journals. Furthermore, another limitation was the small number of cohort studies as most of the included studies were either case series or case reports. This did not provide enough data to calculate the rate of incidence of parenchymal liver injury post-COVID-19 infection. However, the case reports provided enough details about the individual cases, which gave a better insight into the included cases with more details about prognosis and management.

5. Conclusions

This systematic review looked at the acute and chronic parenchymal liver complications of COVID-19. Common chronic complications that were found in patients’ weeks after their COVID-19 infection included liver steatosis, fibrosis, NAFLD, and chronic liver disease. Complications like hepatitis, acute liver failure, and hemorrhage were observed shortly after recovery. Most of the patients were described as recovered or recovering from liver injury. However, two patients with acute liver failure had to undergo liver transplants, and one patient with liver abscess and hemorrhage died. The mechanism of SARS-CoV-2’s direct viral attack affecting the liver centers around the expression of the ACE-2 receptor by the hepatocytes. The indirect mechanisms include the overall inflammatory state of COVID19 infection, drug side effects, and previous comorbidities. The acute complications are usually severe and should be monitored for patients who recently recovered from COVID-19. Chronic complications, like steatosis, fibrosis, and cirrhosis are typically not as symptomatic; thus, it is important for clinicians to monitor patients for these complications. The association between vaccination status and long COVID-19 liver injury is unclear, mostly due to underreporting of vaccination status in the studies. The connection between the severity of COVID-19 and the risk of long COVID-19-related liver injury is not well documented in most studies. Milic et al. found that 18% of patients who developed NAFLD required invasive ventilation, compared to 20% of those who did not develop NAFLD. Further research is necessary to determine whether the severity of COVID-19 influences the likelihood of long-term liver complications. Further studies should focus on how comorbidities and factors surrounding the COVID-19 infection influence the development of liver complications following infection. To gain a more comprehensive understanding of liver injury in post-COVID-19 patients, future studies should incorporate longer follow-up periods, spanning several years after recovering from COVID-19.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/biomedicines12092065/s1, Table S1: Demographic and clinical data for patients reported with parenchymal liver injury reported post-COVID-19 infection.; Supplementary S1: Database search strategy.

Author Contributions

Conceptualization, A.L., A.A., D.Z., M.M., L.Y. and I.M.; methodology, D.Z; software, D.Z.; validation, D.Z.; formal analysis A.L. and D.Z; investigation D.Z.; resources, D.Z.; data curation, A.L. and D.Z.; writing—original draft preparation, A.L, A.A, N.B., B.M., S.A., S.S. and M.N.A.; writing—review and editing, A.L., L.Y., M.M. and D.Z.; visualization, D.Z.; supervision, D.Z.; project administration, D.Z.; cross-checking, M.M., L.Y., I.M., A.A. and A.L.; screening, A.L, A.A, N.B., B.M., S.A., S.S. and M.N.A.; data extraction, A.L, A.A, N.B., B.M., S.A., S.S. and M.N.A. All authors have read and agreed to the published version of the manuscript.

Funding

The publication of this article was funded by the Weill Cornell Medicine–Qatar Health Sciences Library.

Data Availability Statement

All extracted data for this systematic review are submitted as Supplementary Materials.

Acknowledgments

We would like to thank Sa’ad Laws for his help during the early phases of this project, including developing the search strategy and importing papers. We would like also to thank Weill Cornell Medicine-Qatar for the continuous support.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Fung, M.; Babik, J.M. COVID-19 in Immunocompromised Hosts: What We Know So Far. Clin. Infect. Dis. 2021, 72, 340–350. [Google Scholar] [CrossRef] [PubMed]
  2. Gottlieb, M.; Wang, R.C.; Yu, H.; Spatz, E.S.; Montoy, J.C.C.; Rodriguez, R.M.; Chang, A.M.; Elmore, J.G.; Hannikainen, P.A.; Hill, M.; et al. Severe Fatigue and Persistent Symptoms at 3 Months Following Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study. Clin. Infect. Dis. 2023, 76, 1930–1941. [Google Scholar] [CrossRef] [PubMed]
  3. Desai, A.D.; Lavelle, M.; Boursiquot, B.C.; Wan, E.Y. Long-Term Complications of COVID-19. Am. J. Physiol. Cell Physiol. 2022, 322, C1–C11. [Google Scholar] [CrossRef]
  4. Buonomano, P.; Di Stasio, G.D.; Sinisi, A.A.; Rambaldi, P.F.; Mansi, L. Gamma Emitters in the Primary or Secondary Pathologies of the Adrenal Cortex. In Nuclear Medicine and Molecular Imaging: Volume 1–4; Elsevier: Amsterdam, The Netherlands, 2022; Volume 2, pp. 224–238. [Google Scholar]
  5. Zhao, X.; Lei, Z.; Gao, F.; Xie, Q.; Jang, K.; Gong, J. The Impact of Coronavirus Disease 2019 (COVID-19) on Liver Injury in China: A Systematic Review and Meta-Analysis. Medicine 2021, 100, e24369. [Google Scholar] [CrossRef]
  6. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Int. J. Surg. 2010, 8, 336–341. [Google Scholar] [CrossRef]
  7. Wells, G.A.; Shea, B.; O’Connell, D.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses 2021. Available online: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed on 12 August 2024).
  8. Murad, M.H.; Sultan, S.; Haffar, S.; Bazerbachi, F. Methodological Quality and Synthesis of Case Series and Case Reports. BMJ Evid. Based Med. 2018, 23, 60–63. [Google Scholar] [CrossRef] [PubMed]
  9. Ayoubkhani, D.; Khunti, K.; Nafilyan, V.; Maddox, T.; Humberstone, B.; Diamond, I.; Banerjee, A. Post-COVID Syndrome in Individuals Admitted to Hospital with COVID-19: Retrospective Cohort Study. BMJ 2021, 372, n693. [Google Scholar] [CrossRef] [PubMed]
  10. Bai, Y.; Xu, J.; Chen, L.; Fu, C.; Kang, Y.; Zhang, W.; Fakhri, G.E.; Gu, J.; Shao, F.; Wang, M. Inflammatory Response in Lungs and Extrapulmonary Sites Detected by [18F] Fluorodeoxyglucose PET/CT in Convalescing COVID-19 Patients Tested Negative for Coronavirus. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 2531–2542. [Google Scholar] [CrossRef]
  11. Dennis, A.; Cuthbertson, D.J.; Wootton, D.; Crooks, M.; Gabbay, M.; Eichert, N.; Mouchti, S.; Pansini, M.; Roca-Fernandez, A.; Thomaides-Brears, H.; et al. Multi-Organ Impairment and Long COVID: A 1-Year Prospective, Longitudinal Cohort Study. J. R. Soc. Med. 2023, 116, 97–112. [Google Scholar] [CrossRef]
  12. Dennis, A.; Wamil, M.; Alberts, J.; Oben, J.; Cuthbertson, D.J.; Wootton, D.; Crooks, M.; Gabbay, M.; Brady, M.; Hishmeh, L.; et al. Multiorgan Impairment in Low-Risk Individuals with Post-COVID-19 Syndrome: A Prospective, Community-Based Study. BMJ Open 2021, 11, e048391. [Google Scholar] [CrossRef]
  13. Drăgănescu, A.C.; Săndulescu, O.; Bilașco, A.; Kouris, C.; Streinu-Cercel, A.; Luminos, M.; Streinu-Cercel, A. Transient Immune Hepatitis as Post-Coronavirus Disease Complication: A Case Report. World J. Clin. Cases 2021, 9, 4032–4039. [Google Scholar] [CrossRef]
  14. Cooper, S.; Tobar, A.; Konen, O.; Orenstein, N.; Kropach Gilad, N.; Landau, Y.E.; Mozer-Glassberg, Y.; Bar-Lev, M.R.; Shaoul, R.; Shamir, R.; et al. Long COVID-19 Liver Manifestation in Children. J. Pediatr. Gastroenterol. Nutr. 2022, 75, 244–251. [Google Scholar] [CrossRef] [PubMed]
  15. Ahmed, M.; Green, S.R.; Sundar, D. Dilated Cardiomyopathy with Congestive Hepatopathy in Post COVID-19 PatientA Case Report. J. Clin. Diagn. Res. 2022, 16, 4. [Google Scholar] [CrossRef]
  16. Sai, B.V.K.; Kumar, H.; Arun Babu, T.; Chaitra, R.; Satapathy, D.; Kalidoss, V.K. Clinical Profile and Outcome of Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19 Infection: A Single-Center Observational Study from South India. Egypt. Pediatr. Assoc. Gaz. 2023, 71, 4. [Google Scholar] [CrossRef]
  17. Kolesova, O.; Vanaga, I.; Laivacuma, S.; Derovs, A.; Kolesovs, A.; Radzina, M.; Platkajis, A.; Eglite, J.; Hagina, E.; Arutjunana, S.; et al. Intriguing Findings of Liver Fibrosis Following COVID-19. BMC Gastroenterol. 2021, 21, 370. [Google Scholar] [CrossRef]
  18. Daid, S.S.; Toribio, A.D.; Lakshmanan, S.; Sadda, A.; Epstein, A. Spontaneous Intraparenchymal Hepatic Hemorrhage as a Sequela of COVID-19. Cureus 2020, 12, e10447. [Google Scholar] [CrossRef] [PubMed]
  19. Ma, Y.; Zhang, L.; Wei, R.; Dai, W.; Zeng, R.; Luo, D.; Jiang, R.; Wu, H.; Zhuo, Z.; Yang, Q.; et al. Risks of Digestive Diseases in Long COVID: Evidence from a Large-Scale Cohort Study. MedRxiv 2023. [Google Scholar] [CrossRef]
  20. Anguiano-Albarran, R.; Cain, D.; Ashfaq, M.; Modi, A.; Gautam, S. Multiorgan Failure and Omicron: A Suspected Case of Post-COVID-19 Cholangiopathy. Cureus 2023, 15, e35010. [Google Scholar] [CrossRef]
  21. Soldera, J.; Bosi, G.R. Haemophagocytic Lymphohistiocytosis Following a COVID-19 Infection: Case Report. J. Infect. Dev. Ctries. 2023, 17, 302–303. [Google Scholar] [CrossRef]
  22. Radzina, M.; Putrins, D.S.; Micena, A.; Vanaga, I.; Kolesova, O.; Platkajis, A.; Viksna, L. Post-COVID-19 Liver Injury: Comprehensive Imaging with Multiparametric Ultrasound. J. Ultrasound Med. 2022, 41, 935–949. [Google Scholar] [CrossRef]
  23. Pesti, A.; Danics, K.; Glasz, T.; Várkonyi, T.; Barbai, T.; Reszegi, A.; Kovalszky, I.; Vályi-Nagy, I.; Dobi, D.; Lotz, G.; et al. Liver Alterations and Detection of SARS-CoV-2 RNA and Proteins in COVID-19 Autopsies. GeroScience 2023, 45, 1015–1031. [Google Scholar] [CrossRef]
  24. Liemarto, A.K.; Budiono, B.P.; Chionardes, M.A.; Oliviera, I.; Rahmasiwi, A. Liver Abscess with Necrosis in Post COVID-19: A Case Report. Ann. Med. Surg. 2021, 72, 103107. [Google Scholar] [CrossRef] [PubMed]
  25. Roman, A.; Moldovan, S.; Stoian, M.; Tilea, B.; Dobru, D. SARS-CoV-2 Associated Liver Injury: A Six-Month Follow-up Analysis of Liver Function Recovery. Med. Pharm. Rep. 2022, 95, 393–399. [Google Scholar] [CrossRef]
  26. Milic, J.; Barbieri, S.; Gozzi, L.; Brigo, A.; Beghé, B.; Verduri, A.; Bacca, E.; Iadisernia, V.; Cuomo, G.; Dolci, G.; et al. Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome. Open Forum Infect. Dis. 2022, 9, ofac003. [Google Scholar] [CrossRef] [PubMed]
  27. Bende, F.; Tudoran, C.; Sporea, I.; Fofiu, R.; Bâldea, V.; Cotrău, R.; Popescu, A.; Sirli, R.; Ungureanu, B.S.; Tudoran, M. A Multidisciplinary Approach to Evaluate the Presence of Hepatic and Cardiac Abnormalities in Patients with Post-Acute COVID-19 Syndrome—A Pilot Study. J. Clin. Med. 2021, 10, 2507. [Google Scholar] [CrossRef]
  28. Shorbagi, A.I.; Obaideen, A.; Jundi, M. Post-COVID-19 Polyautoimmunity—Fact or Coincidence: A Case Report. Front. Med. 2023, 10, 1013125. [Google Scholar] [CrossRef]
  29. Lai, P.-H.; Ding, D.-C. Acute Liver Injury in a COVID-19 Infected Woman with Mild Symptoms: A Case Report. World J. Clin. Cases 2023, 11, 472–478. [Google Scholar] [CrossRef] [PubMed]
  30. Daga, M.; Mawari, G.; Singh, S.; Hussain, M.; Srivastava, S.; Sonika, U.; Sakhuja, P. A Case of Hepatitis: Post—Acute Sequelae of Asymptomatic COVID-19 Infection. J. Int. Med. Sci. Acad. 2021, 34, 322–325. [Google Scholar]
  31. Han, S.K.; Baik, S.K.; Kim, M.Y. Non-Alcoholic Fatty Liver Disease: Definition and Subtypes. Clin. Mol. Hepatol. 2023, 29, S5–S16. [Google Scholar] [CrossRef]
  32. Hong, T.; Chen, Y.; Li, X.; Lu, Y. The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD. Oxidative Med. Cell. Longev. 2021, 2021, 6889533. [Google Scholar] [CrossRef]
  33. Jothimani, D.; Venugopal, R.; Abedin, M.F.; Kaliamoorthy, I.; Rela, M. COVID-19 and the Liver. J. Hepatol. 2020, 73, 1231–1240. [Google Scholar] [CrossRef]
  34. Glowacka, I.; Bertram, S.; Herzog, P.; Pfefferle, S.; Steffen, I.; Muench, M.O.; Simmons, G.; Hofmann, H.; Kuri, T.; Weber, F.; et al. Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63. J. Virol. 2010, 84, 1198–1205. [Google Scholar] [CrossRef] [PubMed]
  35. Murray, E.; Tomaszewski, M.; Guzik, T.J. Binding of SARS-CoV-2 and Angiotensin-Converting Enzyme 2: Clinical Implications. Cardiovasc. Res. 2020, 116, e87–e89. [Google Scholar] [CrossRef]
  36. Madeddu, P.; Emanueli, C.; El-Dahr, S. Mechanisms of Disease: The Tissue Kallikrein–Kinin System in Hypertension and Vascular Remodeling. Nat. Rev. Nephrol. 2007, 3, 208–221. [Google Scholar] [CrossRef] [PubMed]
  37. Karmouty-Quintana, H.; Thandavarayan, R.A.; Keller, S.P.; Sahay, S.; Pandit, L.M.; Akkanti, B. Emerging Mechanisms of Pulmonary Vasoconstriction in SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) and Potential Therapeutic Targets. Int. J. Mol. Sci. 2020, 21, 8081. [Google Scholar] [CrossRef] [PubMed]
  38. Dawood, R.M.; El-Meguid, M.A.; Salum, G.M.; El Awady, M.K. Key Players of Hepatic Fibrosis. J. Interferon Cytokine Res. 2020, 40, 472–489. [Google Scholar] [CrossRef]
  39. Ginès, P.; Krag, A.; Abraldes, J.G.; Solà, E.; Fabrellas, N.; Kamath, P.S. Liver Cirrhosis. Lancet 2021, 398, 1359–1376. [Google Scholar] [CrossRef]
  40. Gregorio, G.V.; Mieli-Vergani, G.; Mowat, A.P. Viral Hepatitis. Arch. Dis. Child. 1994, 70, 343–348. [Google Scholar] [CrossRef]
  41. Vasques, F.; Cavazza, A.; Bernal, W. Acute Liver Failure. Curr. Opin. Crit. Care 2022, 28, 198–207. [Google Scholar] [CrossRef]
  42. Koyama, Y.; Brenner, D.A. Liver Inflammation and Fibrosis. J. Clin. Investig. 2017, 127, 55–64. [Google Scholar] [CrossRef]
  43. Walker, W.A.; Mathis, R.K. Hepatomegaly. An Approach to Differential Diagnosis. Pediatr. Clin. N. Am. 1975, 22, 929–942. [Google Scholar] [CrossRef]
  44. Fortea, J.I.; Puente, Á.; Cuadrado, A.; Huelin, P.; Pellón, R.; González Sánchez, F.J.; Mayorga, M.; Cagigal, M.L.; García Carrera, I.; Cobreros, M.; et al. Congestive Hepatopathy. Int. J. Mol. Sci. 2020, 21, 9420. [Google Scholar] [CrossRef]
  45. Varga, Z.; Flammer, A.J.; Steiger, P.; Haberecker, M.; Andermatt, R.; Zinkernagel, A.S.; Mehra, M.R.; Schuepbach, R.A.; Ruschitzka, F.; Moch, H. Endothelial Cell Infection and Endotheliitis in COVID-19. Lancet 2020, 395, 1417–1418. [Google Scholar] [CrossRef] [PubMed]
  46. Ackermann, M.; Verleden, S.E.; Kuehnel, M.; Haverich, A.; Welte, T.; Laenger, F.; Vanstapel, A.; Werlein, C.; Stark, H.; Tzankov, A.; et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19. N. Engl. J. Med. 2020, 383, 120–128. [Google Scholar] [CrossRef] [PubMed]
  47. Nardo, A.D.; Schneeweiss-Gleixner, M.; Bakail, M.; Dixon, E.D.; Lax, S.F.; Trauner, M. Pathophysiological Mechanisms of Liver Injury in COVID-19. Liver Int. 2021, 41, 20–32. [Google Scholar] [CrossRef]
  48. Muhović, D.; Bojović, J.; Bulatović, A.; Vukčević, B.; Ratković, M.; Lazović, R.; Smolović, B. First Case of Drug-induced Liver Injury Associated with the Use of Tocilizumab in a Patient with COVID-19. Liver Int. 2020, 40, 1901–1905. [Google Scholar] [CrossRef]
  49. Zoref-Lorenz, A.; Ellis, M.; Jordan, M.B. Inpatient Recognition and Management of HLH. Hematology 2023, 2023, 259–266. [Google Scholar] [CrossRef]
Biomedicines 12 02065 g001
Figure 1. Protocol of database search, screening, and study selection.
Figure 1. Protocol of database search, screening, and study selection.
Biomedicines 12 02065 g001
Biomedicines 12 02065 g002
Figure 2. Types of the reported parenchymal liver injury post-COVID-19 infection and the reported outcomes. Only 1 death was reported by the 22 included studies. NAFLD: non-alcoholic fatty liver disease, NR: not reported.
Figure 2. Types of the reported parenchymal liver injury post-COVID-19 infection and the reported outcomes. Only 1 death was reported by the 22 included studies. NAFLD: non-alcoholic fatty liver disease, NR: not reported.
Biomedicines 12 02065 g002
Biomedicines 12 02065 g003
Figure 3. Types of post-COVID-19 parenchymal liver injury as reported by 22 included studies. The numbers in the figures show the reported number of patients. (a) Post-COVID-19 steatosis and NAFLD as reported by 7 included studies. (b) Post-COVID-19 acute hepatitis with cholestasis and autoimmune hepatitis as reported by 4 included studies. (c) Post-COVID-19 hepatomegaly and increased liver volume as reported by 2 included studies. (d) Post-COVID-19 endothelial damage, sinus dilation, chronic liver disease, or other disorders as reported by 11 included studies. The other disorders were reported only in 8 patients, such as autoimmune hemolytic anemia, acute liver injury with calcified liver nodule, portal venous thrombosis, liver abscesses, hemophagocytic lymphohistiocytosis, deranged LFTs with ascites, and congestive hepatopathy. Liver stiffness was also reported but the number of patients was not reported (NR). Liver fibrosis was reported in 7 patients while sclerosis and cirrhosis post-COVID-19 were reported without reporting the number of patients (4 studies). Acute liver failure was reported by 3 case reports and liver inflammation (by imaging) was reported in 29 patients by 2 studies. The last 3 categories were not presented as pie charts due to the lack of number of patients or because there were no different types to show on the pie chart. NAFLD: non-alcoholic fatty liver disease, NR: not reported.
Figure 3. Types of post-COVID-19 parenchymal liver injury as reported by 22 included studies. The numbers in the figures show the reported number of patients. (a) Post-COVID-19 steatosis and NAFLD as reported by 7 included studies. (b) Post-COVID-19 acute hepatitis with cholestasis and autoimmune hepatitis as reported by 4 included studies. (c) Post-COVID-19 hepatomegaly and increased liver volume as reported by 2 included studies. (d) Post-COVID-19 endothelial damage, sinus dilation, chronic liver disease, or other disorders as reported by 11 included studies. The other disorders were reported only in 8 patients, such as autoimmune hemolytic anemia, acute liver injury with calcified liver nodule, portal venous thrombosis, liver abscesses, hemophagocytic lymphohistiocytosis, deranged LFTs with ascites, and congestive hepatopathy. Liver stiffness was also reported but the number of patients was not reported (NR). Liver fibrosis was reported in 7 patients while sclerosis and cirrhosis post-COVID-19 were reported without reporting the number of patients (4 studies). Acute liver failure was reported by 3 case reports and liver inflammation (by imaging) was reported in 29 patients by 2 studies. The last 3 categories were not presented as pie charts due to the lack of number of patients or because there were no different types to show on the pie chart. NAFLD: non-alcoholic fatty liver disease, NR: not reported.
Biomedicines 12 02065 g003
Table 1. Post-COVID-19 steatosis and NAFLD.
Table 1. Post-COVID-19 steatosis and NAFLD.
StudyStudy Type/CountyN (Total)/Gender (%M)n/N (%)/Type of LPD* Age (Years)Previous Liver DiseaseCOVID-19 SeverityFollow-Up Time/Outcome
[11]Prospective longitudinal study/UKBaseline
536/(27%M)		NR
Liver steatosis		NRNR13% hospitalized196 (182–209) days
Follow-up (over 1 year)
331/(27%M)		NRNRNR NA
[19] ^Large-scale prospective population cohort study/UKCOVID-19 group
112,311/(45.2%M)		NR
NAFLD		NRNRNon-hospitalized
Hospitalized
Severe		254 (IQR 184–366) days
Contemporary control group
359,671/(44.6%M)		NR
NAFLD		NRNRNR254 (184–366) days
Historical control group
370,979/(55%M)		NAFLD56.94NRNR254 (IQR 184–367) days
[22]Observational cohort study/LatviaPost-COVID-19
56/(50%M)		NR
Steatosis		NRNRModerate:
10/30 (33%)
Severe:
7/30 (23%)		NR
Control
34/(38%M)		NR
Steatosis
Fibrosis		NRNRNRNR
[23] ^Observational cohort study/Hungary150/(54%M)99/(66%)
Steatosis (n = 147):
F3: 15
F2: 29
F1: 49
F0: 54		NRNR83 ICUNR
[25] ^Prospective cohort study/Romania78/(56%M)58 (74%)
Hepatic steatosis:
20/(26%)		NRNRNR
60 non-severe
18 severe		6 months
[26]Retrospective cohort study/Italy235/(68.9%M)105/(77%)
NAFLD		61 (52–72.5)NonePatients with IV/NIV: 45NR
105/(63.8%M)
No NAFLD at follow-up		NR
Median reported PACS symptoms: 3		63 (52–74)NonePatients with IV/NIV: 21 (p = 0.9)As above
130/(73.1%M)
NAFLD at follow-up		NR
** NAFLD		60 (52–70) patients with IV/NIV: 24As above
[27]Prospective cohort study/RomaniaPulmonary injury group
53/(43.4%M)		NR
Steatosis		NRNoneNRNR
Non-pulmonary injury group
44/(31.8%M)		NRNRNoneNRNR
ICU: intensive care unit, IV: invasive ventilation, LPD: liver parenchymal disease, M: male, NIV: noninvasive ventilation, NAFLD: non-alcoholic fatty liver disease, NR: not reported. * Mean ± SE/Median (IQR), ** Criteria: Presence of liver steatosis (score > 36 on hepatic steatosis index) + body mass index (BMI) > 25 or type 2 diabetes militis (T2DM). Median reported PACS system: 2. ^ Includes patients with multiple types of parenchymal liver injury.
Table 2. Post-COVID-19 liver fibrosis, sclerosis, and cirrhosis.
Table 2. Post-COVID-19 liver fibrosis, sclerosis, and cirrhosis.
StudyStudy Type/CountyN (Total)/Gender (%M)n/N (%)/Type of LPD* Age (Years)Previous Liver DiseaseCOVID-19 SeverityFollow-Up Time/Outcome
[17]Cross-sectional, single-center study/LatviaAcute COVID-19 group
66/(50%M)		NR
Liver fibrosis		NRNRNRNo follow-up
Post-COVID-19 group
58/(53%M)		NR
Liver fibrosis		NRNRNRNo follow-up
Control group
17/(53%M) 		NRNRNRNRNo follow-up
[19] ^Large-scale prospective population-based cohort study/UKCOVID-19 group
112,311/(45.2%M)		NR
Hepatic sclerosis or cirrhosis		NRNRNon-hospitalized
Hospitalized
Severe		254 (IQR 184–366) days
Contemporary control group
359,671/(44.6%M)		NR
Hepatic sclerosis or cirrhosis 		NRNRNR254 (184–366) days
Historical control group
370,979/(55%M)		Hepatic sclerosis or cirrhosis56.94NRNR254 (IQR 184–367) days
[22]Observational cohort study/LatviaPost- COVID-19
56/(50%M)		NR
Fibrosis		NRNRModerate:
10/30 (33%)
Severe:
7/30 (23%)		NR
Control
34/(38%M)		NR
Fibrosis		NRNRNRNR
[23]Observational cohort study/Hungary150/(54%M)99 (66%)
Cirrhosis
F4 fibrosis: 7
F3 fibrosis: 3
F1/2 fibrosis: 68
No fibrosis/F0: 72		NRNR83 cases ICU NR
ICU: intensive care unit, LPD: liver parenchymal disease, M: male, NR: not reported. * Mean ± SE/Median (IQR). ^ Includes patients with multiple types of parenchymal liver injury.
Table 3. Post-COVID-19 hepatitis.
Table 3. Post-COVID-19 hepatitis.
StudyStudy Type/CountyN (Total)/Gender (%M)n/N (%)/Type of LPD* Age (Years)Previous Liver DiseaseCOVID-19 SeverityFollow-Up Time/Outcome
[13]Case report/Romania1 M1/(100%)
Immune hepatitis		21NoneMild COVID-19ALT normalization 20 days after peak on follow-up
[14]Retrospective case series/Israel5/(100%M)
Patient 3:
Acute hepatitis with cholestasis		8NoneMild4 months
Patient 4:
Acute hepatitis with cholestasis		8NAFLDMild4 months
Patient 5:
Acute hepatitis with cholestasis		13NoneMild45 days
[27]Case report/UAE1/(100%M)1/(100%)
Autoimmune hepatitis		33NoneMild7 months after hospitalization (asymptomatic)
[30]Case report/India1 F1/(100%)
Acute hepatitis		25NRMild5 months after presentation
ALT: alanine transaminase, F: female, LPD: liver parenchymal disease, M: male, NR: not reported. * Mean ± SE/Median (IQR).
Table 4. Post-COVID-19 acute liver failure.
Table 4. Post-COVID-19 acute liver failure.
StudyStudy Type/CountyN (Total)/Gender (%M)n/N (%)/Type of LPD* Age (Years)Previous Liver DiseaseCOVID-19 SeverityFollow-Up Time/Outcome
[14]Retrospective case series/Israel5/(100%M)5/(100%)
Patient 1: Acute liver failure		Patient 1: 3-month-oldNoneMildNR
Patient 2: Acute liver failurePatient 2: 5-month-oldNoneNRNR
[19] ^Large-scale prospective population-based cohort study/UKCOVID-19 group
112,311/(45.2%M)		NR
Liver failure		NR NRNon-hospitalized
Hospitalized
Severe		254 (IQR 184–366) days
Contemporary control group
359,671/(44.6%M)		NR
Liver failure		NRNRNR254 (184–366) days
Historical control group
370,979/(55%M)		Liver failure56.94NRNR254 (IQR 184–367) days
[20]Case report/USA1 F1 (100%)
Acute liver failure 		68 NRNR
F: female, LPD: liver parenchymal disease, M: male, NR: not reported. * Mean ± SE/Median (IQR). ^ Includes patients with multiple types of parenchymal liver injury.
Table 5. Post-COVID-19 liver inflammation by imaging.
Table 5. Post-COVID-19 liver inflammation by imaging.
StudyStudy Type/CountyN (Total)/Gender (%M)n/N (%)/Type of LPD* Age (Years)Previous Liver DiseaseCOVID-19 SeverityFollow-Up Time/Outcome
[10] ^Prospective study/ChinaCOVID-19 cohort
7/(42%M)		7/(100%)
** Liver inflammation by imaging		66 (56–88)HLD: 0/7 (0%)Severe16.1 days after discharge (on average)
[12] ^Prospective observational cohort study/UKExperimental cohort (post-COVID-19 syndrome patients)
201/(29.4%M)		56/(28%)
Increased liver inflammation (≥784 ms cT1) 11.5%		NRNRNR
19% hospitalized 		NR
Control cohort (healthy individuals)
36/(88.6%M)		NR
Increased Liver inflammation (≥784 ms cT1) 0%		NRNRNRNR
HLD: Hyperlipidemia, M: male, NR: not reported. * Mean ± SE/Median (IQR). ** SUVavg, SUVmax in liver—significantly higher (p < 0.05) vs. controls. No significant difference b/w CTmax and CTavg vs. controls. LPD: liver parenchymal disease. ^ Includes patients with multiple types of parenchymal liver injury.
Table 6. Post-COVID-19 hepatomegaly.
Table 6. Post-COVID-19 hepatomegaly.
StudyStudy Type/CountyN (Total)/Gender (%M)n/N (%)/Type of LPD* Age (Years)Previous Liver DiseaseCOVID-19 SeverityFollow-Up Time/Outcome
[11] ^Prospective longitudinal study/UKBaseline
536/(27%M)		NRNRNR13% hospitalized due to COVID-19196 (182–209) days
Follow-up (over 1 year)
331/(27%M)		20/(14%)
Hepatomegaly		NRNR NR
[12] ^Prospective observational cohort study/UKExperimental cohort (post-COVID-19 syndrome patients)
201/(29.4%M)		56/(28%)
Increased liver volume (≥1935 mL) 10.4%		NRNRNR
19% of patients hospitalized 		NR
Control cohort (healthy individuals)
36/(88.6%M)		NR
Increased liver volume (≥1935 mL) 2.9%		NRNRNRNR
LPD: liver parenchymal disease, M: male, NR: not reported. * Mean ± SE/Median (IQR). ^ Includes patients with multiple types of parenchymal liver injury.
Table 7. Other parenchymal liver post-COVID-19 complications.
Table 7. Other parenchymal liver post-COVID-19 complications.
StudyStudy Type/CountyN (Total)/Gender (%M)n/N (%)/Type of HPD* Age (Years)Previous Liver DiseaseCOVID-19 SeverityFollow-Up Time/Outcome
[9]Retrospective cohort study/UKExperimental group (COVID-19 group)
47,780/(54.9%M)		143/(0.3%)
Chronic liver disease
NR		NRNR10% of patients needed ICUMean follow-up 140 ± 50 days
Maximum 253 days
Matched control group (individuals who did not test positive for COVID-19)
47,780/(54.9%M)		NRNRNRNRMean follow-up 153 ± 33 days
Maximum 253 days
[15]Case study/India1/(100%M)Congestive hepatopathy17NoneMild COVID-193 months Discharged
[16]Single-center prospective observational study/India78/(34.6%M)NR
Deranged LFTs: 40/78
Ascites: 1/78		NRNRNRNo follow-up
[18]Case study/USA1 F100%
Intraparenchymal liver hemorrhage		43 Severe COVID-19 infectionUntil discharge only
[21]Case report/Brazil1 M1/(100%)
hemophagocytic lymph histiocytosis 		57NoneMild COVID-19 infectionNR
[23] ^Observational cohort study/Hungary150/(54%M)99/(66%)
Endothelial damage (n = 119):
F3: 46
F2: 52
F1: 21
F0: 0
Sinus dilatation (n = 119):
F3: 31
F2: 52
F1: 36
F0: 0		NRNR83 cases requiring ICUNR
[24]Case report/Indonesia1 M1/(100%)
Liver abscesses with hemorrhage and parenchymal necrosis		49NoneSevere COVID-19 pneumonia admitted to ICUDied on day 20
[25] ^Prospective cohort study/Romania78/(56%M)58/(74%)
Portal venous system thrombosis: 2 (2.5%)		NRNRNR
60 non-severe
18 severe		6 months
[27] ^Prospective cohort study/RomaniaPulmonary injury group
53/(43.4%M)		NR
Liver stiffness		NRNoneNRNR
Non-pulmonary injury group
44/(31.8%M)		NR
Liver stiffness		NRNoneNRNR
[29]Case report/Taiwan1 F1/(100%)
Acute liver injury + calcified liver nodule		60NoneMildOver 3 months,
LFTs trended down until returning to normal by the last follow-up visit
[30]Case report/India1 F1/(100%)
Autoimmune hemolytic anemia		25NRMild5 months after presentation
F: female, ICU: intensive care unit, LFTs: liver function tests, M: male, NR: not reported. * Mean ± SE/Median (IQR). ^ Includes patients with multiple types of parenchymal liver injury.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lebbe, A.; Aboulwafa, A.; Bayraktar, N.; Mushannen, B.; Ayoub, S.; Sarker, S.; Abdalla, M.N.; Mohammed, I.; Mushannen, M.; Yagan, L.; et al. New Onset of Acute and Chronic Hepatic Diseases Post-COVID-19 Infection: A Systematic Review. Biomedicines 2024, 12, 2065. https://doi.org/10.3390/biomedicines12092065

AMA Style

Lebbe A, Aboulwafa A, Bayraktar N, Mushannen B, Ayoub S, Sarker S, Abdalla MN, Mohammed I, Mushannen M, Yagan L, et al. New Onset of Acute and Chronic Hepatic Diseases Post-COVID-19 Infection: A Systematic Review. Biomedicines. 2024; 12(9):2065. https://doi.org/10.3390/biomedicines12092065

Chicago/Turabian Style

Lebbe, Ahamed, Ali Aboulwafa, Nuran Bayraktar, Beshr Mushannen, Sama Ayoub, Shaunak Sarker, Marwan Nour Abdalla, Ibrahim Mohammed, Malik Mushannen, Lina Yagan, and et al. 2024. "New Onset of Acute and Chronic Hepatic Diseases Post-COVID-19 Infection: A Systematic Review" Biomedicines 12, no. 9: 2065. https://doi.org/10.3390/biomedicines12092065

APA Style

Lebbe, A., Aboulwafa, A., Bayraktar, N., Mushannen, B., Ayoub, S., Sarker, S., Abdalla, M. N., Mohammed, I., Mushannen, M., Yagan, L., & Zakaria, D. (2024). New Onset of Acute and Chronic Hepatic Diseases Post-COVID-19 Infection: A Systematic Review. Biomedicines, 12(9), 2065. https://doi.org/10.3390/biomedicines12092065

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop